Sana Biotechnology, Inc. (NASDAQ:SANA) Receives $14.00 Average Price Target from Brokerages

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) have received an average rating of “Moderate Buy” from the seven research firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $10.80.

Several equities research analysts recently weighed in on SANA shares. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of Sana Biotechnology in a research note on Tuesday. Jefferies Financial Group started coverage on shares of Sana Biotechnology in a research report on Friday, March 14th. They issued a “buy” rating and a $7.00 target price on the stock. Citizens Jmp raised shares of Sana Biotechnology from a “market perform” rating to an “outperform” rating and set a $5.00 price target for the company in a research report on Tuesday. Finally, TD Cowen raised shares of Sana Biotechnology from a “hold” rating to a “buy” rating in a research note on Wednesday, January 8th.

Sana Biotechnology Trading Down 3.4 %

Shares of SANA opened at $2.26 on Friday. Sana Biotechnology has a 1-year low of $1.52 and a 1-year high of $10.50. The firm’s 50-day moving average price is $2.98 and its 200-day moving average price is $3.19. The firm has a market capitalization of $504.59 million, a price-to-earnings ratio of -1.61 and a beta of 1.63.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings data on Monday, March 17th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.02. On average, research analysts forecast that Sana Biotechnology will post -1.16 EPS for the current fiscal year.

Insider Transactions at Sana Biotechnology

In related news, insider Fmr Llc sold 290,912 shares of the stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $6.49, for a total transaction of $1,888,018.88. Following the sale, the insider now directly owns 4,541,511 shares of the company’s stock, valued at $29,474,406.39. This trade represents a 6.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 31.10% of the company’s stock.

Hedge Funds Weigh In On Sana Biotechnology

A number of hedge funds have recently bought and sold shares of SANA. Cerity Partners LLC purchased a new stake in shares of Sana Biotechnology during the 4th quarter valued at about $25,000. Tower Research Capital LLC TRC grew its position in Sana Biotechnology by 229.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 15,136 shares of the company’s stock worth $25,000 after purchasing an additional 10,548 shares during the period. Syon Capital LLC bought a new stake in shares of Sana Biotechnology in the fourth quarter worth $27,000. Wilmington Savings Fund Society FSB purchased a new stake in shares of Sana Biotechnology during the 3rd quarter valued at about $29,000. Finally, Ameriprise Financial Inc. purchased a new stake in Sana Biotechnology during the fourth quarter valued at approximately $29,000. Hedge funds and other institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.